Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Capmatinib (Primary) ; Bevacizumab
- Indications Colorectal cancer; Glioblastoma; Gliosarcoma; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors SCRI Development Innovations
- 11 May 2017 Planned End Date changed from 1 May 2018 to 1 Nov 2019.
- 11 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Sep 2018.
- 24 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov